Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

6(85.7%)

Phase 2

1(14.3%)

7Total

Phase 1(6)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT03760523Phase 1Terminated

Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia

Role: collaborator

NCT03117920Phase 2Completed

A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer

Role: lead

NCT05566834Phase 1Unknown

Minnelide™ Capsules Alone and in Combination With Paclitaxel in Advanced Gastric Cancer

Role: lead

NCT03129139Phase 1Unknown

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors

Role: lead

NCT05557851Phase 1Unknown

Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas

Role: lead

NCT03347994Phase 1Withdrawn

Minnelide in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia

Role: collaborator

NCT01927965Phase 1Completed

Study of Minnelide™ in Patients With Advanced GI Tumors

Role: lead

All 7 trials loaded